Abivax SA Posts Wider Loss Despite Rise in Operating Income

Biotech firm Abivax SA reports a wider loss for fiscal 2024, yet its operating income has increased. Investors should consider the implications of higher expenses on stock performance.

Date: 24-03-2025

AI Rating: 5

Performance Overview: Abivax SA reported a significant increase in its fiscal losses for 2024, showing a deeper impact from rising expenses.

The total loss reached 176.2 million euros, compared to a loss of 147.8 million euros in the previous year. This escalation is primarily attributed to higher interest expenses, non-cash expenses, and increased transaction costs.

Operating Income Analysis: On a positive note, the company's operating income experienced a 13 percent increase, climbing to 12.5 million euros from 4.6 million euros in fiscal 2023. This growth was driven by additional research credits and increased subsidies, indicating a potential for future revenue enhancement, despite the overall loss.

The company's operating loss also widened to 172.9 million euros from 127.4 million euros the previous year. This widening indicates that while there are areas of growth, the overall financial health might still be concerning for investors, as losses are deepening.

Stocks: ABVX